Comment for best oral presentation award of JSSX meeting 2019
Daiichi Sankyo Europe
First of all, we would like to express our gratitude to be honored by the Japanese Society for the Study of Xenobiotics with the best oral presentation award for the presentation on our innovative in vitro gut model. The title of our talk was “Human biopsy-derived intestinal organoid monolayer as unique in vitro model to predict drug absorption and induction of drug metabolizing enzymes and transporters”. The human biopsy-derived intestinal organoid monolayer platform was established at Daiichi Sankyo Europe´s, Tissue and Cell Research Center Munich based in Martinsried by Munich, Germany, where our colleagues are working on making the drug discovery and development more effective and efficient by using and developing translational models bridging the preclinical research with the clinics. But what is so innovative about this in vitro intestinal organoid monolayer model? It is well know that the human small intestine is the major site of oral drug absorption and expresses several clinically relevant drug metabolizing enzymes and transporters. Common screening models for the evaluation of drug absorption in the gut lack the physiological expression pattern of those and are therefore not ideal to predict e.g. intestinal drug-drug interactions. To overcome these limitations, our team has developed human biopsy-derived 3D intestinal organoids in monolayer configuration which are mimicking the intestinal barrier and can be used not only for prediction of intestinal drug-drug interactions but also for evaluation of the vectorial transport of drugs. The best oral presentation award of JSSX meeting 2019 motivates us to continue our research especially with focus on prediction of intestinal absorption, gastro-intestinal toxicity and interplay of drug transporters with drug metabolizing enzymes in the human gut. Last but not least would like to thank the ADME & In Vitro Solutions team at Daiichi Sankyo Europe´s, Tissue and Cell Research Center Munich especially Dr. Fatima Ahmetlic and Dr. Nora Semren for initiating and establishing the human intestinal organoid monolayer platform, Dr. Katja Damme for highly valuable scientific input and supervision and Mr. Stefan Beck for his excellent technical assistance. In addition, we would like to thank our colleagues at Daiichi Sankyo´s Drug Metabolism and Pharmacokinetics Research Laboratories in Tokyo, Japan, especially Dr. Yumi Nishiya, Dr. Kengo Watanabe and Dr. Nobuaki Watanabe for their long-term support and expertise.